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Summary: Serum was obtained from 155 children at the time of admission to hospital for elective surgery.
The concentration of serum keratan sulphate was determined by an ELISA which uses an antibody specific
for keratan sulphate, a molecule found predominantly in cartilage. Concentrations of keratan sulphate rise
progressively during the first four years of life (0—2: mean = 357 μg/l; 2—4: mean = 422 μg/l) and then
remain high until 12 years of age (mean = approx. 500 μg/l). At this time, concentrations drop markedly
(13-year olds: mean = 3?7μ§^1; 14-year olds: mean = 318μg/l). After age 15, concentrations continue to
fall toward the concentrations found in normal adults. Serum concentrations did not show significant
differences with respect to disease category, sex or race but were found to vary, sometimes markedly, from
child to child at any one age. The results suggest human cartilage undergoes significant changes in metabolic
activities during maturation. Measurements of keratan sulphate concentration in serum may prove useful in
studying the biochemical and physiological bases of these changes and in monitoring growth or endochondral
ossification during maturation.
Introduction molecules consist of a core protein (MT = 2.5-3.8
Cartilage proteoglycans are large molecular weight x 105) to which glycosaminoglycans, namely chon-
macromolecules that endow cartilage with its ability droitin sulphate and keratan sulphate, and both Ο-
ίο undergo reversible deformation (1). These complex and N-linked oligosaccharides are covalently attached
- (1). The rate at which cartilage proteoglycans turn
') Eugene J-M. A. Thonar is principal investigator and recipient over at different ages remains a point of much con-
of support for work from The William Noble Lane Medical tention (2 — 5). The absence in normal cartilage matrix
(LMP). glycans (6) suggests that individual proteoglycan mol-
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ecules are normally rapidly degraded into smaller
fragments that are either engulfed by the chondrocytes
or, more likely, diffuse into the body fluids that are
in contact with the cartilage (5). Indeed, proteoglycan
fragments and glycosaminoglycans are present in syn-
ovial fluid (7, 8) and several species of glycosaminog-
lycans have been detected in peripheral blood (5,
9-12).
A number of glycosaminoglycans, i.e. chondroitin
sulphate, hyaluronic acid and heparan sulphate, have
been detected in the blood in significant amounts
(9 — 12). All of these glycosaminoglycans are constit-
uents of proteoglycans in non-cartilaginous tissues (1).
In contrast, keratan sulphate is only found in signif-
icant amounts in proteoglycans of cartilage and cor-
nea (1, 5). Because the great majority (> 95%) of
keratan sulphate-containing proteoglycans are found
in hyaline, fibrous or elastic cartilages (1, 5), meas-
urements of keratan sulphate blood concentrations
might prove particularly useful to monitor cartilage
catabolism. An enzyme-linked immunosorbent assay
(ELISA)-inhibition assay, which utilizes a monoclonal
antibody specific for keratan sulphate, was developed
to quantify keratan sulphate present as single chains
in human serum (5). In a previous study (5), we
presented evidence that concentrations of keratan sul-
phate in sera from adult hospitalized patients vary
from individual to indiviudal but do not show any
significant differences with respect to age or sex. In
the same study, we reported that apart from a group
of patients with degenerative cartilage changes, i. e.
osteoarthritis, there were no significant differences
between groups representing different non-rheuma-
tological conditions. We also presented preliminary
data which suggested that the concentration of ker-
atan sulphate in the sera of children aged 5 — 12 was
significantly higher than in adults (5).
The present publication describes studies aimed at
quantifying keratan sulphate in the serum of children
of different ages. We present evidence that levels of
keratan sulphate undergo a number of significant
changes during growth and development.
Patients and Methods
Materials
Flat bottom ELISA Nunc-Immunoplates IF (with certificate of
binding capacity) were obtained from Vanguard International,
Grand Island, NY; Tween 20 (polyoxyethylene sorbitan mono-
laureate) and o-phenylenediamine were from Sigma, St. Louis,
MO; and chondroitinase ABC (Proteus vulgaris) was from ICN
Immunobiologicals, Lisle, Illinois.
Subjects
Blood samples were drawn from 155 children (76 males and 79
females) at the time of admission to Children's Memorial Hos-
pital, Chicago, for elective surgery. No children with rheuma-
tological conditions were included in this study. In all cases,
blood was drawn prior to subsequent surgical intervention and
serum was isolated within 3 hours. Disease categories, shown
in table 1, represent primary diagnoses as determined by the
attending physician. Race as well as height and weight were
also recorded at the time of bleeding. Patients were categorized
by age into 9 groups, using 2 year increments (tab. 2). Age
group 2-4, for example, includes all children who at the time
of bleeding had turned 2 but were younger than 4 years. Drugs
taken just prior to and at the time of bleeding were also recorded
and were categorized according to their area of activity as
shown in table 1. Serum was isolated from blood drawn from
19 young normal adults aged 23—27; there were 7 males and
12 females.
Antigens
A purified international standard of costal cartilage keratan
sulphate antigen used as a standard in all the ELISA-inhibition
assays was a kind gift from Drs. M. B. M thews and A. L.
Horwitz, The University of Chicago. The antigenic solution of
chondroitinase ABC-treated bovine nasal Dl proteoglycan (5)
used to coat the Nunc ELISA plates was prepared as follows.
Bovine nasal Dl proteoglycan (4 mg) was dissolved into 160 μΐ
buffer containing 0.8 units chondroitinase ABC, .1 mol/1 so-
dium acetate, and 0.1 mol/1 Tris, pH 7.3. The digestion was
allowed to proceed for 2 hours at 37 °C. Immediately prior to
coating, this solution was diluted into 20 mmol/1 carbonate-
bicarbonate coating buffer, 0.2 g/1 sodium azide, pH 9.2, to
bring the concentration of bovine nasal Dl . proteoglycan to
5 |
Antibodies
A previously described (5, 13) monoclonal IgGl antibody (I/
20/5-D-4) that specifically recognizes an antigenic determinant
in the polysaccharide structure of both corneal and skeletal
keratan sulphate was used as the source of anti-keratan sulphate
antibody. Peroxidaser-coupled rabbit anti-mouse IgG was ob-
tained from ICN Immunobiologicals, Lisle, IL.
ELISA-inhibition assay
Both the ELISA technique and the inhibition assay performed
in conjunction with it were performed exactly as previously
described (5). On day 1 of the assay, samples and standards of
costal cartilage keratan sulphate, at different concentrations,
are mixed with an equal volume of monoclonal antibody in
phosphate buffered saline, 0.5 ml/1 Tween 20 (14) and placed
at 4 °C overnight. On day 2, plates pre-coated with the chon-
droitinase ABC-treated bovine nasal Dl proteoglycan (see
above) (5) are washed 3 times and 200 μ! of each antigen-
antibody mixture is placed into a well. After one hour, the
plates are again washed and 200 μΐ of peroxidase-coupled anti-
mouse IgG is pipetted in each well (5, 14). One hour later, the
plates are washed for a final time and 200 μΐ of a solution
containing substrate for the peroxidase is placed in each well
(5, 14). The production of chromophore is stopped after 30 —
60 minutes by the addition of 50 μΐ of 2 mol/l H2SO4. The
concentration of keratan sulphate present in the unknowns is
calculated by comparing the absorbance value in each case to
values generated from known concentrations of costal cartilage
keratan sulphate antigen treated in an identical fashion and
incorporated in the same plate. In order to assess-precision of
the ELISA-inhibition assay for keratan sulphate, replicate
measurements on the same serum sample were performed and
compared within the same run (12 measurements performed in
the same ELISA plate), between runs (20 measurements per-
formed in different ELISA plates on the same day) and on
different days (10 measurements performed fen different days).
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Statistical analysis
The data obtained were analyzed statistically (15) to determine
whether the levels of keratan sulphate varied significantly with
respect to age (one way analysis of variance and multiple range
test). Because statistically significant age-related differences
were found (see Results), the keratan sulphate value for each
patient was recalculated as the percentage of the mean keratan
sulphate concentration for that age. The recalculated keratan
sulphate values of the whole population were then analyzed
statistically to determine whether they varied with respect to
sex (Student's t-test), primary disease (analysis of variance),
race (analysis of variance) and drug intake (analysis of vari-
ance). In order to determine if there were relationships between
height and weight and serum concentrations of keratan sul-
phate, the height and weight of each child was recalculated as
a percentage of the mean height and weight for that age using
the National Center for Health percentiles (16). The recalcu-
lated keratan sulphate values for the whole population were
then analyzed statistically to determine whether they varied
with respect to percentile height or weight (regression analysis).
In addition, the taller (> 75 percentile, n = 13, mean age
= 5.9) and smaller (< 10 percentile, n = 27, mean age = 6.5)
children in the 0—12 age range were compared to determine if
they differed with respect to their recalculated keratan sulphate
concentrations.
Results
Precision of the ELISA-inhibition assay was good
when repeated measurements of keratan sulphate
present in a serum sample were performed on the
same day in either the same microtiter plate (mean
± standard deviation = 444 ±5.3 μ§/1 keratan sul-
phate, n = 12) or different microtiter plates (mean ±
standard deviation = 444 ± 8.2 μ§/1 keratan sul-
phate, η = 20). Precision was also good when the
serum was analyzed in different plates on different
days (mean ± standard deviation = 446 ±11.5 μ§/1
keratan sulphate, n = 10). Because the amounts of
keratan sulphate in the purified standard preparation
and in serum were too low to measure by conventional
biochemical techniques, we were unable to assess ac-
curacy.
The children's age, sex, race, height and weight were
recorded and their overall status at the time of blood
donation further clinically classified as shown in table
1. Of the 155 donors, 48 (31 %) had been given med-
ication of one sort or another as listed in table 1. The
concentration of immunoreactive keratan sulphate in
the serum of the 155 children tested was found to
vary markedly with age (tab. 2). During the first 4
years of life, concentrations rise progressively, appear
to peak at about age 4—5 and remain elevated until
about age 12. At this time, concentrations begin to
decrease. This decrease was most pronounced in the
13-year olds (12-year olds: mean = 491 ± 128 μ§/1,
n = 10; 13-year olds: mean = 377 ± 170 μ§/1, η = 9;
14-year olds: mean =318 ±87 μg/l, η = 9). After
Tab. 1. Classification of pediatric patients by age, primary diagnosis and concurrent drug therapy.
Patients were categorized by age into 9 groups, using 2 year increments. Age group 2—4, for example, reflects all children
who at the time of bleeding had turned 2 but were younger than 4. Primary diseases described as others included bone
fracture, cystic fibrosis, nevi, burns, haem ngiomas, hydrocephalus, seizure disorder, paralysis and asthma. Of the total
patient population, only 31% had received concurrent drug therapy as indicated.
Drug therapy
Total
(n)
Age groups
(n)
0-2 2-4 4-6 6-8 8-10 10-12 12-14 14-16 16-18
Primary disease 155
Congenital malformations
a ) Skeletal 4 7 9 1 7 4 6 7 6 6 1
b ) Cardiac 1 9 2 3 4 5 1 2 0 1 1
c ) Urinary tract 2 0 0 7 2 4 3 2 1 1 0
d ) Other 1 2 1 0 2 3 1 0 3 1 1
Infection 7 2 1 1 1 1 0 0 0 1
Malignancy 4 0 0 1 0 0 0 2 1 0
Non-malignant tumour 2 0 0 0 0 0 0 1 0 1
Cerebral palsy 8 1 2 1 1 1 0 1 1 0
Others 3 6 ' 1 3 4 4 3 1 1 5 2 3
48
Gastrointestinal agents
CNS agents
Hormonal agents
Antimicrobial agents
Nutritional agents
Spasmolytics
Cardiovascular agents
Respiratory tract agents
Adrenergic blockers
4
7
3
17
2
6
5
1
3
1
0
0
2
2
0
0
0
0
0
0
0
3
0
2
1
0
1
1
1
0
3
0
0
1
0
0
0
2
0
2
0
1
1
0
0
1
0
0
2
0
2
1
0
0
1
2
0
5
0
1
0
0
0
0
1
1
0
0
0
0
1
0
0
1
0
0
0
0
1
0
1
0
0
2
0
0
0
0
0
1
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age 15, concentrations continue to fall, approaching
the lower values obtained for the 19 young normal
adults (tab. 2, fig. 1). In order to statistically evaluate
these observed maturation-related differences, chil-
dren were categorized into 9 groups, using 2-year
increments. Analysis (one way analysis of variance)
of the data showed that there were significant differ-
ences between some of the age-groups (p < 0.00005).
A Tukey-B procedure (multiple range test) was then
performed to establish which age groups were signif-
icantly different from others. The results revealed that
children between the ages of 4—6, 6—8, 8 — 10 and
10—12 have significantly higher concentrations of
serum keratan sulphate than children in the 0—2 or
14—18 age groups (p < 0.05). Differences between
the other age groups shown in table 2 were not sta-
tistically significant (p > 0.05).
Keratan sulphate concentrations recalculated as the
percentage of the mean keratan sulphate concentra-
tion for that age were analyzed to determine whether
there were any differences in the whole population
with respect to sex, race, disease category and drug
administered. The results showed that keratan sul-
phate concentrations do not vary significantly be-
tween males and females (t-test: p = 0.135) nor be-
tween children of different races (analysis of variance:
p = 0.390). Importantly, there were no significant
differences between the groups of children with dif-
ferent diseases (analysis of variance: p = 0.646) nor
between groups which received different drugs in the
course of therapy (analysis of variance: p = 0.818).
Keratan sulphate concentrations vary, sometimes
markedly, from child to child of the same age (fig. 1).
This suggests that there may be significant differences
Tab. 2. Age-related changes in concentrations of immunoreac-
tive keratan sulphate in serum.
Age
group
(a)
0- 2
2- 4
4- 6
6- 8
8-10
10-12
12-14
14-16
16-18
*23-27'
η
16
17
22
22
16
22
19
13
8
19
Keratan
χ
Oig/1)
357
422
502
507
493
547
437
332
310
228
sulphate
+ SD
Otg/1)
96
119
114
126
114
176
157
97
107
72
Range
fog/l)
266-556
258-691
295-767
243-745
288-749
313-987
221-795
122-546
205-525
103-396
* Young normal adults aged 23—27 were included as a single
separate group for comparison. The values given under
"Range" refer to the lowest and highest concentrations of
keratan sulphate recorded for each age-group.
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Fig. 1. Concentration of immunoreactive keratan sulphate
in serum of 155 children, hospitalized at different
ages, and 19 normal young adults aged 23—27. Con-
centration refers to μg of skeletal, keratan sulphate
standard per liter and was calculated as described in
Patients and Methods. The mean for the different age
groups of the pediatric population is indicated by the
solid line with one standard deviation above and below
the mean indicated by the broken line.
in the rate of catabolism of cartilage proteoglycans
from child to child. While it was not possible to assess
rate of growth at the time of bleeding, statistical
analyses were performed to assess whether there were
correlations between serum keratan sulphate conceit
trations and height at any one age. Because both
parameters vary significantly with age, the keratan
sulphate concentration and height of each patient
were first recalculated as the percentage of the mean
fceratan sulphate concentration or height for that age
(16). The results of the statistical analyses (regression)
performed on the whole population suggest that there
may be a correlation between keratan sulphate con-
centration and height at any one age (p = 0.067).
This is supported by the observation that, in children
between the ages of 0—12, the mean of recalculated
keratan sulphate concentrations of the group of tallest
children (> 75 percentile) was 18% higher than the
mean of the group of smallest children (< 10 percen-
tile) (113% vs 95%). In contrast, but not unexpect-
edly, when weights were considered, there was no
correlation between recalculated keratan -sulphate
concentrations and weights recalculated for each child
as a percentage of the average weight for that age
(p = 0.665). > <
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Discussion
The contention that measurements of concentrations
of keratan sulphate in peripheral blood provide direct
information about the rate of cartilage proteoglycan
catabolism (5) is based, in part, upon the premise that
when cartilage proteoglycans are degraded, during
normal turnover or in pathological states, the great
majority of the breakdown products are not engulfed
by the chondrocytes but rapidly diffuse out of the
cartilage matrix (6). A recent study has shown that
pathological synovial fluids from patients with carti-
lage degeneration or erosion, i. e. osteoarthritis, rheu-
matoid arthritis and juvenile rheumatoid arthritis,
contain elevated amounts of proteoglycan fragments
varying in size and composition (17). These fragments
all appear to contain a protein backbone to which
are covalently attached several chondroitin sulphate
and/or keratan sulphate chains. How and where these
are further degraded to yield the smaller chondroitin
sulphate (9) and keratan sulphate (5, 18, 19) chains
which are found in the circulation is not known.
The monoclonal antibody (1/20/5-D-4) used in this
study has been used previously to quantify keratan
sulphate in serum (5, 20). This well characterized
antibody has been shown to be very specific for a
portion of the keratan sulphate chain containing a
sequence of three or more repeating units of the
disaccharide sulphated N-acetyl glucosamine-sul-
phated galactose (21). This epitope has not been found
in any glycoprotein or other polysaccharide (13, 20,
21). Desulphation of the keratan sulphate chain re-
sults in total loss of antigenicity (13). On the other
hand, the protein to which the keratan sulphate chain
is covalently attached is not essential for recognition.
Thus, we have shown the ELISA-inhibition assay can
be used to quantify keratan sulphate in intact proteo-
glycans (5), keratan sulphate in peptidoglycans pro-
duced by digestion of preoteoglycan with trypsin (22)
or single keratan sulphate chains free of protein (5).
We have also shown, using the ELISA-inhibition as-
say, that no antigenic keratan sulphate can be detected
in the serum of individuals with macular corneal
dystrophy (20). The single abnormality in this inher^
ited blinding disease appears to be an absence of
sulphate ester groups on the 6 position of both N-
acetyl galactosamine and galactose moieties of the
keratan sulphate chain; the metabolism of all other
carbohydrates appears to be normal in this condition
(20).
Two recent, reports offer evidence that when a carti-
laginous tissue is rapidly degraded, the concentration
of serum keratan sulphate rises concomitantly (23,
24). In the first study, a single injection of chymo-
papain in one intervertebral disc caused a several-
fold, rapid increase in concentrations of serum kera-
tan sulphate in each of 10 human patients undergoing
chemonucleolysis (23). Concentrations reached a peak
48 —72 h following the injection, remained elevated
for at least one week but returned to pre-injection
values at 21 days. In the second study, serum concen-
trations were found to rise markedly during the rapid
growth and elongation of antlers in male deer (24).
Deer antler regeneration is an annual event which
occurs through a process of endochondral ossification
(24). Upon completion of mineralization of the antler,
serum keratan sulphate levels returned to normal.
These reports add considerable strength to the con-
tention that increases in the rate of catabolism of
cartilage proteoglycans will result in a corresponding
increase in the concentrations of keratan sulphate in
the circulation.
The studies presented here present evidence that con-
centrations of serum keratan sulphate undergo
marked maturation-related changes. Because of ethi-
cal considerations, we were unable to perform this
study on normal children. Our results which show
that there were no significant differences in serum
keratan sulphate concentrations between the different
disease groups (p = 0.646) suggest that the matura-
tion-related changes we have observed are a good
reflection of changes in the paediatric population as
a whole.
The results strongly suggest that measurements of
serum concentrations of keratan sulphate provide im-
portant new information about various aspects of the
metabolism and/or catabolism of cartilage proteogly-
cans in children. For example, the finding that the
concentration of serum keratan sulphate is higher in
children than adults is in itself of great significance
and should prove extremely useful in assessing age-
related differences in proteoglycan catabolism in vivo.
None of the 115 children aged 0 — 12 had serum
keratan sulphate concentrations that were lower than
the mean obtained for the group of normal young
adults aged 23 — 27. Studies on age-related changes
have shown that cartilage proteoglycans from a 10-
year old contain less than half as much keratan sul-
phate as the proteoglycans from human adult carti-
lage (25). Consequently, the greater than 2-fold dif-
ference in the keratan sulphate serum concentrations
of a 10-year old (approx. 520 g/l) and a young adult
(approx. 228 g/l) (5) suggests the amount of cartilage
proteoglycan catabolized per kg of body weight is at
least four times higher in the 10-year old. Because the
ratio of cartilage mass to body weight or blood vol-
ume is considerably higher in the growing child (26)
than in the adult, it is difficult to establish the extent
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to which the decrease in the concentration of keratan
sulphate in serum between age 10 and adulthood is
the result of
i) a lower rate of catabolism of proteglycan per unit
mass of cartilage in the adult (2—5) and/or
ii) an age-related decrease in mass of cartilage per
unit body weight.
Elongation of the long bones during growth occurs
through a process of endochondral ossification in
which new cartilage is continuously laid down before
it is degraded and replaced by bone (27). The presence
of a transient rise in serum concentrations of keratan
sulphate during endochondral ossification of the an-
tlers in male deer (24) or experimentally-induced deg-
radation of an intervertebral disc (23, 28) support the
contention that concentrations of serum keratan sul-
phate can be correlated with the extent and/or rate
of cartilage catabolism. Further support for the con-
tention that serum concentrations of keratan sulphate
in children may be correlated with metabolic activities
in the growing cartilages comes from a recent report
that children with constitutional growth delay have
significantly lower serum keratan sulphate concentra-
tions than age-matched controls (29). Additional
studies are needed to test the contention that concen-
trations of serum keratan sulphate may provide direct
or indirect information about the rate of growth of
children between the ages of 0 —12. If that contention
can be substantiated, measurements of serum concen-
trations of keratan sulphate could prove particularly
useful to study diseases of cartilage metabolism which
result in abnormalities of growth and elongation of
the long bones in children.
The rapid decrease in keratan sulphate concentrations
in the 13 — 16 year-old group is of great interest for
it suggests that a decrease in the rate of catabolism
of cartilage proteoglycaris actually occurs some time
after growth has begun to decline, L e. approximately
15 — 16 years of age in males and 13-7,14 years of age
in females (16), although linear growth can continue
until age 25. There are no known major changes in
the content or composition of cartilage proteoglycans
between 13 and 16 years of age (25). Consequently,
it is likely the decrease reflects a change in rate of
proteoglycan metabolism, possibly under hormonal
regulation. There appear to be no clear sex-related
differences in the time of onset of this decrease; how-
ever, in this study, the number of males and females
in the 13 —16 age group was too small to allow for
meaningful statistical analyses.
Finally, the ELISA^inhibition assay for keratan suU
phate should prove useful*in determining whether
some drugs, i.e. non-steroidal anti-inflammatory
agents such as acetylsalicylic acid (aspirin®) or indo-
metacin, which have been shown to profoundly affect
proteoglycan metabolism in vitro (30^32), have any
effect on growing children in vivo.
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